|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TBX2 overexpression correlated with tumor invasion, advanced tumor node metastasis stage and presence of lymph node metastasis.
|
30651856 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, we showed that the TBX2 subfamily genes play a critical tumor suppressor role in lung cancer pathogenesis through regulating its methylating pattern, making them putative candidates for epigenetic therapy in LUAD.
|
30425966 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EGR1 interacts with TBX2 and functions as a tumor suppressor in rhabdomyosarcoma.
|
29719592 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The enriched genes included MMP9, SERPINE2, CAV1, KRT14, and RASA3 in basal tumors, and PPARG, LY6E, CTSE, CDK3, and TBX2 in luminal tumors.
|
30089113 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At the molecular level, we discovered that expressions of several tumor suppressor genes, including <i>p21, p27</i>, <i>phosphatase with tensin homology (PTEN)</i> and <i>E-Cadherin</i>, were increased dramatically after TBX2 knockdown in above NPC cells.
|
28881763 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Blocking endogenous TBX2 expression in PC3 and ARCaP<sub>M</sub> prostate cancer cell models using a dominant-negative construct resulted in decreased tumor cell proliferation, colony formation, and invasion <i>in vitro</i> Blocking endogenous TBX2 in human prostate cancer mouse xenografts decreased invasion and abrogation of bone and soft tissue metastasis.
|
28108510 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicated that the expression rates of TBX2 were significantly increased in the cancerous tissues, compared with the healthy tumor adjacent tissue, and TBX2 increased staining was associated with the clinical stage and pathological grade.
|
28849151 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The high expression of TBX2 in NSCLC was significantly correlated with lymph node metastasis and tumor node metastasis (TNM) stage.
|
25027744 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TBX2 was a significantly prognostic factor for decreased survival and increased disease recurrence independent of tumor stage(II, III stage) and functioned as a biomarker to identify prognosis of patients with CRC (OS: HR 2.154; 95% CI 1.019-4.551; P = 0.044, DFS: HR 2.253; 95% CI 1.109-4.575; P = 0.025).
|
23959449 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ChIP analysis and cell-based reporter assays further revealed that TBX2 directly represses transcription of E-cadherin, a tumor suppressor gene, whose loss is crucial for malignant tumor progression.
|
22844464 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression level of Tbx2 had a significant positive relationship with tumor differentiation degree, higher TNM stage and distant metastasis.
|
19469638 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results indicate that the cancer cells expressing KAI1 attach to vascular endothelial cells through direct interaction between KAI1 and DARC, and that this interaction leads to inhibition of tumor cell proliferation and induction of senescence by modulating the expression of TBX2 and p21.
|
16862154 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Support for this hypothesis comes from studies demonstrating that many of the amplified genes are over-expressed in breast cancer cell lines and tumors, and that the RPS6KB1, TBX2, and PPM1D genes from the region, that are amplified and over-expressed in breast tumors and cell lines, contribute to tumor formation and/or tumor progression.
|
12755490 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator.
|
12000749 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
S6K, PAT1, and TBX2 were coamplified in about 10% of tumors, whereas RADS1C amplification was seen in only 3% of tumors.
|
11034067 |
2000 |